-
Insight into FDA Orange Book patents and grasp the pulse of original drugs
Time of Update: 2021-06-05
Therefore, Orange Book patents have become a very important information channel for understanding the original research drugs marketed in the United States.
-
Rituximab "upgraded version"!
Time of Update: 2021-06-05
Due to the impact of biosimilar drugs, sales have begun to decline; Gazyva has always been regarded as an upgraded version of Rituxan, which is Roche's response to the cannibalization of its CD20 market.
-
Among the top 10 domestically produced Class 1 new drug companies, these 3 are amazing!
Time of Update: 2021-06-05
0 Chinese Drug Evaluation Database 60 domestically produced Class 1 new drugs involve more than 40 companies (in terms of the group), and 10 companies including Hengrui, Hausen, BeiGene, Simcere, Beida, Gery, and Hutchison Whampoa have been approved for 2 varieties And above.
-
With the escalation of the Sino-US trade war, China may expand access to the Indian drug market
Time of Update: 2021-06-05
, The relevant government agencies of the two sides are actively formulating specific measures to promote Sino-Indian pharmaceutical trade cooperation and allow more Indian drugs to enter the Chinese market.
-
Novartis' new-generation drug Beovu Phase 3 MERLIN study: Intraocular inflammation is higher than aflibercept
Time of Update: 2021-06-05
The active pharmaceutical ingredient of Beovu is brolucizumab (RTH258), which is a humanized single-chain antibody fragment (scfv) that targets all types of vascular endothelial growth factor-A (VEGF-A).
-
Zejing Pharmaceutical's Class 1 new drug ``Donafinil Tosylate Tablets'' will soon be approved for advanced hepatocellular carcinoma
Time of Update: 2021-06-05
This new drug marketing application is mainly based on the results of an open, randomized, parallel controlled, multi-center phase II/III clinical study of Donafenib tosylate tablets for the first-line treatment of advanced hepatocellular carcinoma (trial code ZGDH3).
-
Jinfang Pharmaceutical's KRAS G12C inhibitors apply for clinical Amgen, Novartis and other corporate layouts
Time of Update: 2021-06-05
In July 2019, Mirati Therapeutics and Novartis reached a clinical collaboration to evaluate the combination therapy of MRTX849 and TNO155 (a SHP2 inhibitor) in the treatment of patients with advanced solid tumors with KRAS G12C mutations.
-
Rise across the board!
Time of Update: 2021-06-05
Sales of terminal insulin and similar drugs in public medical institutions in China (unit: ten thousand yuan) Source: Mi Nei. com, China's public medical institutions terminal competition pattern Due to the high technical barriers to insulin products, the three foreign companies, Novo Nordisk, Sanofi, and Eli Lilly, have long occupied the dominant position in the domestic insulin market.
-
AstraZeneca China reached a cooperation with Boan Biotechnology on bevacizumab injection
Time of Update: 2021-06-05
Exclusive promotion rights.
It is reported that bevacizumab injection is a recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting vascular endothelial growth factor (VEGF), which can inhibit its binding to VEGF receptors by binding to VEGF-A.
-
Qilu Pharmaceutical's new anti-cancer drug imported for USD 235 million applied for clinical application
Time of Update: 2021-06-05
Article source: Pharmaceutical GuanlanAccording to the announcement of the Center for Drug Evaluation (CDE) of the State Drug Administration of China, Qilu Pharmaceutical submitted a clinical trial application for CEND-1 for injection, which was accepted on May 27.
-
Latest news: Zhendong Pharmaceutical terminates asset swap and related party transactions!
Time of Update: 2021-06-04
Zhendong Pharmaceutical originally planned to divest its long-term loss-making asset Ante Pharmaceutical.
Zhendong Pharmaceuticals stated that the sales of fenoxin minoxidil liniment under Ante Pharmaceuticals for the treatment of hair loss were poor in the past few years.
-
Yiling Pharmaceutical won the "2021 China Brand (Industry) Top Ten Innovative Enterprises"
Time of Update: 2021-06-04
On May 27th, the “China Enterprise News” group, the special issue department of Consumer Daily, the column group of “Discover Brands”, the online version of the People’s Daily Market News Brand Power · Independent Brand Selection Demonstration Project, University of International Business and Economics China International Brand Strategy The 2021 (eighth) Chinese brand influence evaluation results release event jointly sponsored by the Research Center and other units was held in Beijing.
-
Three kinds of drug instructions including haloperidol tablets add medication information for children
Time of Update: 2021-06-04
People's Daily Online, Beijing, June 2 (Reporter Hongli Sun) A few days ago, the State Food and Drug Administration issued an announcement that haloperidol tablets, risperidone oral preparations and fluoxetine oral preparations can increase the number of children and the dosage as required .
-
Cinda Biotech obtains exclusive license for ROS1/NTRK inhibitors from Baoyuan Pharmaceuticals in Greater China
Time of Update: 2021-06-04
The trial includes a phase 2 clinical trial in China with indications for NTRK-positive solid tumors, and a phase 2 clinical trial with indications for first-line and second-line ROS1-positive non-small cell lung cancer in the world.
-
Yangtze River's Class 1 new drug "Levoornidazole Disodium Phosphate for Injection" was approved for marketing
Time of Update: 2021-06-04
In addition, levornidazole disodium phosphate has the following advantages over the clinically used ornidazole sodium chloride injection and levornidazole sodium chloride injection: 1) the lipophilicity is enhanced, compared with ornidazole and Levoornidazole has significantly reduced toxicity and prolonged drug metabolism; 2) Impurity studies have shown that it will not produce toxic degradation product 2-methyl-5nitroimidazole; 3) The pH value when it is prepared into an intravenous preparation Around 5.
-
Hausen "Erlotinib Hydrochloride Tablets" Approved for Listing
Time of Update: 2021-06-04
On May 31, Hausen's "Erlotinib Hydrochloride Tablets" was approved by the National Medical Products Administration (NMPA), becoming the second domestic generic drug of this variety.
-
The liberalization of the three-child policy has far-reaching impact in these medical fields...
Time of Update: 2021-06-04
In this regard, since the liberalization of the two-child policy, the National Health Statistics Yearbook data has changed significantly: In 2017, the number of outpatient visits in general hospitals in China was 240 million, the proportion of pediatric outpatients in general outpatient visits increased from 8.
-
Guangdong's export of Chinese medicinal materials ranks first in the country
Time of Update: 2021-06-04
The reporter learned on the 31st that according to statistics from the Guangdong Branch of the General Administration of Customs, from January to April 2021, the value of Chinese medicinal materials exported nationwide was 1.
-
Drug Administration: Issued the "Administrative Measures for Drug Inspection (Trial)"
Time of Update: 2021-06-04
Medical Network, May 31, May 28, in order to implement the "Drug Administration Law" and the "Vaccine Administration Law", further standardize drug inspection behavior, and promote drug regulatory wo
-
Pharmacy filing is not active?
Time of Update: 2021-06-04
Therefore, it is very necessary for MAH (Holder of Drug Marketing Authorization) to hire a large number of medical representatives to conduct academic promotion to doctors and patients, and to analyze the product's characteristics, advantages, usage and dosage, indications, contraindications, precautions for use, and adverse reactions.
